IDEAYA Biosciences, Inc. Common Stock vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| IDYA | JNJ | |
|---|---|---|
| Market Cap | $3.66 billion | $653.35 billion |
| Revenue (TTM) | $234.13 million | $97.93 billion |
| Net Income (TTM) | $-175,020,000 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| IDYA | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.72 |
| Price / Book | 3.05 | 7.69 |
| Price / Sales | 15.63 | 6.67 |
IDYA and JNJ split the valuation factors evenly.
Profitability
| IDYA | JNJ | |
|---|---|---|
| Net Margin | -74.75% | 21.48% |
| Return on Equity | -14.60% | 24.76% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| IDYA | JNJ | |
|---|---|---|
| Dividend Yield | — | 1.96% |
| Payout Ratio | — | 62.18 |
IDYA and JNJ split the dividend factors evenly.
Risk & Sentiment
| IDYA | JNJ | |
|---|---|---|
| Short Interest | 0.14% | 0.67% |
IDYA leads on 1 of 1 risk & sentiment factors.
Dig deeper: IDYA overview, IDYA financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.